In ulcerative colitis, treating beyond endoscopic healing has shown a reduction of relapse and hospitalization, pushing for histological remission to be embraced in clinical practice and clinical trials. Here, we propose the concept of disease clearance (symptomatic, endoscopic and histological remission) as the ultimate goal in the treatment of ulcerative colitis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Developing hydrogels for gene therapy and tissue engineering
Journal of Nanobiotechnology Open Access 15 April 2024
-
“Dual sensitive supramolecular curcumin nanoparticles” in “advanced yeast particles” mediate macrophage reprogramming, ROS scavenging and inflammation resolution for ulcerative colitis treatment
Journal of Nanobiotechnology Open Access 07 September 2023
-
A mannitol-modified emodin nano-drug restores the intestinal barrier function and alleviates inflammation in a mouse model of DSS-induced ulcerative colitis
Chinese Medicine Open Access 11 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ungaro, R. et al. A Treat-to-target update in ulcerative colitis: a systematic review. Am. J. Gastroenterol. 114, 874–883 (2019).
Peyrin–Biroulet, L., Bressenot, A. & Kampman, W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin. Gastroenterol. Hepatol. 12, 929–934 (2014).
Strober, B. E. et al. Clinical goals and barriers to effective psoriasis care. Dermatol. Ther. 9, 5–18 (2019).
Boni, E. Elewski et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. J. Dermatolog Treat. 28, 492–499 (2017).
Shelton, S. K. et al. Ixekizumab: a review of its use for the management of moderate to severe plaque psoriasis. Ann. Pharmacother. 53, 276–284 (2019).
Peyrin-Biroulet, L. et al. Clinical remission as defined by the Mayo Score: do we deceive ourselves? Inflamm. Bowel Dis. 21, 2–3 (2015).
Ma, C. et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment. Pharmacol. Ther. 50, 5–23 (2019).
Fernandez-Blanco, J. I. et al. Adalimumab for induction of histological remission in moderately to severely active ulcerative colitis. Digestive Diseases Sci. 63, 731–737 (2018).
Arijs, I. et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut 67, 43–52 (2018).
Schoepfer, A. M. et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J. Crohns Colitis 6, 412–418 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. L.P.-B. reports personal fees from AbbVie, Allergan, Alma, Amgen, Arena, Biogen, Boerhinger Ingelheim, Celgene, Celltrion, Enterome, Ferring, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, MSD, Nestle, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Takeda and Tillots; grants from Abbvie, MSD and Takeda; and stock options from CTMA. G.R. declares no competing interests.
Supplementary Information
Rights and permissions
About this article
Cite this article
Danese, S., Roda, G. & Peyrin-Biroulet, L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol 17, 1–2 (2020). https://doi.org/10.1038/s41575-019-0211-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0211-1
This article is cited by
-
Developing hydrogels for gene therapy and tissue engineering
Journal of Nanobiotechnology (2024)
-
“Dual sensitive supramolecular curcumin nanoparticles” in “advanced yeast particles” mediate macrophage reprogramming, ROS scavenging and inflammation resolution for ulcerative colitis treatment
Journal of Nanobiotechnology (2023)
-
A mannitol-modified emodin nano-drug restores the intestinal barrier function and alleviates inflammation in a mouse model of DSS-induced ulcerative colitis
Chinese Medicine (2023)
-
Hydrogel–metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis
Journal of Nanobiotechnology (2022)
-
Association between serum bilirubin and mucosal healing among Japanese patients with ulcerative colitis: a cross-sectional study
International Journal of Colorectal Disease (2021)